Ocugen, Inc. (OCGN)

OCU500 Nasal COVID-19 Vaccine Chosen By NIH To Start Clinical Trials


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
October 11, 2023
Report ID: 26152
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

Ticker
OCGN
Current Price
$1.1815 24.49%
Market Cap
$303.1M
Price Target
Refer to Report
Volume
12.7M
52wk Range
$0.345 - $1.1
Related Research Reports
2/12/2024

Raising Price Target to $8 Based On Clinical Progress
Raising Price Target to $8 Based On Clinical Progress (OCGN)
12/20/2023

OCU400 Receives RMAT Designation, OCU410 Treated First Patient
OCU400 Receives RMAT Designation, OCU410 Treated First Patient (OCGN)
11/10/2023

3Q23 Reported With Several Products On Schedule To Reach Clinical Milestones In 2024
3Q23 Reported With Several Products On Schedule To Reach Clinical Milestones In 2024 (OCGN)
10/11/2023

OCU500 Nasal COVID-19 Vaccine Chosen By NIH To Start Clinical Trials
OCU500 Nasal COVID-19 Vaccine Chosen By NIH To Start Clinical Trials (OCGN)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.